Physician profile
Niraj Shah
NPI 1134440969
$5,383.71
in general payments reported to CMS, 2019-2025
30 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $264 · 2021: $205 · 2022: $102 · 2023: $2,139 · 2024: $1,789 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,154.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,599.31 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Novo Nordisk INC | $664.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $580.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $573.30 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $275.76 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $200.56 | 2023-2024 | Austedo Xr, Ajovy, Austedo |
| Allergan, INC. | $185.99 | 2019-2020 | |
| Amgen INC. | $168.36 | 2019-2024 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $162.37 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $129.31 | 2023-2024 | |
| Astellas Pharma US INC | $118.10 | 2023-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.58 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.26 | 2019-2024 | Jardiance |
| Ironwood Pharmaceuticals, INC | $67.74 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $55.37 | 2023 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $47.57 | 2019 | |
| Tris Pharma INC | $45.28 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $41.41 | 2019 | |
| Merck Sharp & Dohme LLC | $37.90 | 2019 | |
| Axsome Therapeutics, INC. | $37.05 | 2023-2024 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $36.03 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $31.38 | 2024 | Rexulti |
| Amarin Pharma, INC. | $30.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.67 | 2019 | |
| Genentech USA, INC. | $20.21 | 2020 | |
| Dexcom, INC. | $17.73 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $15.52 | 2024 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $15.30 | 2024 | Eliquis |
| Glaxosmithkline, LLC. | $14.98 | 2019 | |
| Medtronic, INC. | $14.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.